Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
7 p, 242.6 KB Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies / Boeckx, N. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Koukakis, R. (Biostatistics, Amgen Ltd) ; Op de Beeck, K. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Rolfo, C. (Department of Oncology, Antwerp University Hospital, Edegem) ; Van Camp, G. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Douillard, J.-Y. (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ; André, T. (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ; Peeters, M. (Department of Oncology, Antwerp University Hospital, Edegem)
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of Oncology, Vol. 28 (april 2017) , p. 1862-1868  
7 p, 814.0 KB Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial / Siena, Salvatore (Università degli Studi di Milano (Italy)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Bodoky, Gyorgy (Szent László Hospital (Hungary)) ; Cunningham, David (Royal Marsden National Health Service Foundation Trust (United Kingdom)) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander)) ; Ruff, Paul (University of the Witwatersrand (South Africa)) ; Canon, Jean Luc (Grand Hôpital de Charleroi. Service d'Oncologie-Hématologie (Belgium)) ; Koukakis, Reija (Amgen Ltd. Department of Biostatistics (United Kingdom)) ; Demonty, Gaston (Amgen GmbH. Medical Development (Suïssa)) ; Hechmati, Guy (Amgen GmbH. Global Health Economics (Suïssa)) ; Douillard, Jean-Yves (Institut de Cancérologie de l'Ouest (France)) ; Universitat Autònoma de Barcelona
Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. [...]
2016 - 10.1136/esmoopen-2016-000041
ESMO Open, Vol. 1, Issue 2 (March 2016) , art. e000041  
6 p, 180.0 KB Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas / Ramanathan, R. K. (Mayo Clinic (USA)) ; Goldstein, D. (Prince of Wales Hospital (Australia)) ; Korn, R. L. (Scottsdale Medical Imaging, Ltd (USA)) ; Arena, F. (NYU Langone Arena Oncology (USA)) ; Moore, M. (Provencial Health Services Authority. BC Cancer Agency (Canada)) ; Siena, S. (Università degli Studi di Millano. Niguarda Cancer Center (Italy)) ; Teixeira, L. (Hôpital Saint-Antoine (France)) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Van Laethem, J.-L. (University Clinic of Brussels. Hôpital Erasme (Belgium)) ; Liu, H. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; McGovern, D. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; Lu, B. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; Von Hoff, D. D. (Translational Genomics Research Institute and Honor Health (USA)) ; Universitat Autònoma de Barcelona
In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. [...]
2016 - 10.1093/annonc/mdw020
Annals of Oncology, Vol. 27, Issue 4 (April 2016) , p. 648-653  

Vegeu també: autors amb noms similars
1 Siena, S
1 Siena, Salvatore
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.